益气生血法联合FOLFOX化疗对胃癌肿瘤标志物和免疫调控的影响  

Effect of Yiqi Shengxue method combined with FOLFOX chemotherapy on tumor markers and immune regulation of gastric cancer

作　　者：陈颖 刘正爱 方亮[1] 吴继雄[1] 许珍珍 CHEN Ying;LIU Zheng-ai;FANG Liang;WU Ji-xiong;XU Zhen-shen(Department of Gastroenterology,Huanggang Central Hospital,Huanggang 438000,China;Department of Gastroenterology.Jingzhou Hospital of Traditional Chinese Medicine.Jingzhou 434000,China)

机构地区：[1]黄冈市中心医院消化内科,湖北黄冈438000 [2]荆州市中医医院消化内科,湖北荆州434000

出　　处：《中国中西医结合消化杂志》2020年第5期374-377,共4页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

摘　　要：[目的]观察益气生血法联合FOLFOX化疗对胃癌肿瘤标志物和免疫调控的影响。[方法]选取我院68例中晚期胃癌患者作为研究对象,分为观察组、对照组(各34例)。对照组采用FOLFOX化疗方案进行治疗,观察组采用益气生血法联合FOLFOX化疗进行治疗,比较2组的疗效、肿瘤标志物癌胚抗原(CEA)、糖类抗原(CA12-5、CA15-3、CA19-9)、血细胞簇分化抗原(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)及自然杀伤细胞(NK)的水平。[结果]观察组总有效率为76.5%(26/34)显著高于对照组的50.0%(17/34)(P<0.05)。治疗前2组CEA、CA12-5、CA15-3、CA19-9比较,差异无统计学意义;治疗后2组CEA、CA12-5、CA15-3、CA19-9均下降(P<0.05);治疗后观察组CEA、CA12-5、CA15-3、CA19-9均低于对照组(P<0.05)。治疗前2组CD3^+、CD4^+、CD8^+、CD4^+/CD8^+及NK细胞比较差异无统计学意义,治疗后观察组CD3^+、CD4^+、CD4^+/CD8^+及NK细胞均增高,CD8^+下降;对照组CD3^+、CD4^+、CD4^+/CD8^+及NK细胞均下降,CD8^+增高(P<0.05);治疗后观察组免疫调控指标均优于对照组(P<0.05)。[结论]益气生血法联合FOLFOX化疗改善胃癌的疗效,降低血清中肿瘤标志物的表达,提高机体的免疫功能。[Objective]to observe the effect of Yiqi Shengxue method combined with FOLFOX chemotherapy on tumor markers and immune regulation of gastric cancer.[Methods]Sixty-eight patients with advanced gastric cancer in our hospital were divided into observation group and control group.The control group was treated with FOLFOX chemotherapy.The observation group was treated with the method of Invigorating Qi and promoting blood circulation combined with FOLFOX chemotherapy.The therapeutic effect,tumor marker CEA,carbohydrate antigen(CA12-5,CA15-3,CA19-9),blood cell cluster differentiation antigen(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)and natural killer cell(NK)were compared between the two groups.[Results]the total effective rate of the observation group was 76.5%(26/34)significantly higher than that of the control group 50.0%(17/34)(P<0.05).There was no significant difference in CEA,CA12-5,CA15-3 and CA19-9 between the two groups before treatment(P>0.05);after treatment,CEA,CA12-5,CA15-3 and CA19-9 decreased in the two groups(P<0.05);after treatment,CEA,CA12-5,CA15-3 and CA19-9 in the observation group were lower than those in the control group(P<0.05).There was no significant difference in CD3^+、CD4^+、CD8^+、CD4^+/CD8^+and NK cells between the two groups before and after treatment(P>0.05).After treatment,the CD3^+、CD4^+、CD4^+/CD8^+ and NK cells in the observation group increased,while CD8^+decreased;the CD3^+、CD4^+、CD4^+/CD8^+and NK cells in the control group decreased,and CD8^+ increased(P<0.05);after treatment,the immune regulation indexes in the observation group were better than those in the control group(P<0.05).[Conclusion]Yiqi Shengxue method combined with FOLFOX chemotherapy can improve the curative effect of gastric cancer,reduce the expression of tumor markers in serum and improve the immune function of the body.

关 键 词：胃癌 益气生血法 肿瘤标志物 免疫调控 FOLFOX化疗 疗效 

分 类 号：R735.2[医药卫生—肿瘤]